
|Articles|July 1, 1999
Supplements and Featured Publications
- Evaluating the Health Benefits of Atypical Agents in the Treatment and Management of Psychoses
- Volume 5
- Issue 10 Suppl
Introduction
Advertisement
Articles in this issue
over 26 years ago
Participating Facultyover 26 years ago
Assessment of Quality-of-Life Outcomes in Schizophrenic Patientsover 26 years ago
The Emerging Role of Psychiatric Pharmacistsover 26 years ago
CME/CE Quizover 26 years ago
Selected Abstractsover 26 years ago
BibliographyNewsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Cytokines Linked With Drug Resistance in Ovarian Cancer, but Underlying Mechanisms Remain Unclear
2
Mepolizumab Reduces Health Care Resource Utilization, Work Impairment in Severe Asthma
3
CHEST 2025 Highlights: Future of Respiratory Vaccines and the Impact of Federal Funding Cuts
4
FDA Expands Sotatercept Indication for PAH
5















































